|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.675 USD | +4.04% |
|
-10.53% | -8.61% |
| Apr. 22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
| Apr. 12 | Top Premarket Decliners | MT |
On March 14, 2024, Adial Pharmaceuticals, Inc. closed the transaction. The transaction included participation from a single investor. The company has paid $23,000 sales commissions to the agent in the transaction.
It includes cash fee equal to 7% & a 1% management fee of the aggregate gross proceeds of the private placement.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.61% | 6.53M | |
| -2.62% | 103B | |
| +1.53% | 95.28B | |
| +1.46% | 22.15B | |
| -15.72% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -12.94% | 16.05B | |
| +5.14% | 13.68B | |
| +33.73% | 12.17B |
ADIAL PHARMACEUTICALS, INC. 
